SCHEMBL4724593

SCHEMBL4724593

CCOc1on[c]c1-c1cccc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.44
S1PR3 Q99500 1/20 0.44
ENPP1 P22413 1/20 0.42
HPGD P15428 4/20 0.38
MAPT P10636 4/20 0.38
KDM4E B2RXH2 3/20 0.38
TP53 P04637 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
NPC1 O15118 1/20 0.38
ALOX15 P16050 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
TSHR P16473 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
TLR8 Q9NR97 1/20 0.36
FDPS P14324 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724526 0.89 S1PR1 (0.38) S1PR1S1PR3ENPP1HPGDMAPT
SCHEMBL4720726 0.88 TLR8 (0.39) S1PR1S1PR3HPGDMAPTKDM4E
SCHEMBL4724379 0.84 ALOX15 (0.40) S1PR1S1PR3ENPP1HPGDMAPT
SCHEMBL4721792 0.76 KDM4E (0.41) HPGDMAPTKDM4ETP53ALDH1A1
SCHEMBL4723619 0.72 ENPP1 (0.39) S1PR1S1PR3ENPP1HPGDMAPT
SCHEMBL4724855 0.72 ENPP1 (0.44) S1PR1S1PR3ENPP1HPGDMAPT
SCHEMBL4720960 0.72 ENPP1 (0.42) S1PR1S1PR3ENPP1HPGDMAPT
SCHEMBL4724759 0.72 ENPP1 (0.39) S1PR1S1PR3ENPP1HPGDMAPT
SCHEMBL4724628 0.71 ENPP1 (0.49) S1PR1S1PR3ENPP1HPGDKDM4E
SCHEMBL4723129 0.71 ENPP1 (0.44) S1PR1S1PR3ENPP1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 S1PR1 618/4885S1PR3 346/4885ENPP1 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.